ArticleCureus2022
Fibrolamellar Hepatocellular Carcinoma in the Absence of Risk Factors: A Case Report.
Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer of the liver and intrahepatic bile ducts is the sixth most frequently diagnosed cancer worldwide. In addition, primary liver cancer is the fourth leading cause of cancer-related mortality worldwide, and the second most lethal tumor after pancreatic cancer. Early diagnosis and rapid workup for the suspected case are the only paths for treating the patient with curative intent. Hepatocellular carcinoma (HCC) is usually associated with risk factors like chronic viral hepatitis and alcohol ingestion. Since HCC typically progresses silently, clinical diagnosis can be challenging, and the diagnosis may require the use of one or more imaging modalities and liver biopsy. In this case, the patient is a 29-year-old man with no risk factors, who was diagnosed early and treated without the need for a liver transplant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.